Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-10-02 Annual Report
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Annual Report to Shareholders 91 pages 10.8MB
Annual Report Classification · 100% confidence The document is titled 'Orthocell | Annual Report 2025' and contains detailed sections typical of an annual report, including company overview, board of directors, product portfolio, CEO letter, financial year review, consolidated financial statements, auditor's report, directors' report, and corporate governance statement. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial statements and auditor's report confirms it is the official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K).
2025-10-02 English
Another Record Revenue Quarter for Orthocell 4 pages 696.9KB
Earnings Release Classification · 95% confidence The document is an ASX announcement reporting record revenue for the quarter ended 30 September 2025. It provides detailed financial performance data for the quarter, including revenue figures, growth rates, and market expansion updates. The document mentions that a full Quarterly Activity Report and Appendix 4C will be released in the next 1-2 weeks, indicating this is a preliminary earnings announcement rather than a full interim report. The content focuses on quarterly financial highlights and operational updates without presenting comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2025-10-01 English
First Distributor signed for Remplir in $75m Canadian Market 3 pages 643.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the appointment of a Canadian distributor for Orthocell's nerve repair product Remplir. It discusses market expansion, regulatory approval (Medical Device Licence from Health Canada), and sales expectations. There are no financial statements, quarterly or annual results, or detailed financial data presented. The content focuses on a commercial and operational update regarding distribution and market entry rather than financial performance or regulatory filings. The document is longer than 5,000 characters and is a substantive announcement about a capital/financing-related commercial development (market expansion and distribution appointment). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-09-29 English
Application for quotation of securities - OCC 9 pages 23.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Orthocell Limited regarding the application for quotation of securities on the ASX. It details the securities issued, transferred, or re-classified due to options exercised or convertible securities converted, including numbers, issue dates, and other related information. The document is a formal application for listing new securities rather than a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, as it relates to new securities being quoted and changes in capital structure. The document length is 9286 characters, which is substantive and contains detailed information about the securities but is not a financial report or earnings release. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-09-29 English
Cleansing Notice 2 pages 597.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement titled 'Notice under Section 708A(5)(e) of the Corporations Act' dated 30 September 2025. It details the issuance of new shares following the cashless exercise of unlisted options and provides legal notice under the Corporations Act regarding the exemption for resale of these shares. The content is a formal regulatory notice about a share issue event, specifically a notice under section 708A(5)(e) of the Corporations Act, which is a common regulatory filing for share issuances without disclosure. The document length is 3868 characters, which is relatively short and focused on the announcement of the share issue and related legal compliance, not a full financial report or detailed capital update. This fits the category of a Share Issue/Capital Change announcement rather than a full Capital/Financing Update report or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-09-29 English
Remplir Use in Prostate Surgery Signals Global Opportunity 4 pages 668.2KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Orthocell Limited about the use of their product Remplir in nerve-sparing prostate cancer surgery. It discusses clinical applications, market potential, ongoing data collection, and future plans. There are no financial statements, quarterly or annual results, or regulatory filings such as 10-K or interim reports. The content is focused on product development, clinical use, and market expansion rather than financial performance or governance. It is not a call transcript, audit report, or management report. The document is a corporate announcement about a product and its market opportunity, which fits best under the category of a general regulatory announcement or miscellaneous corporate update. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (over 11,000 characters) and detailed content support this classification with high confidence.
2025-09-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.